Positive preliminary results for investigational vaccine in Phase III HLA-A2 positive non-small cell lung cancer study

In the Atalante-1 study, preliminary Step-1 analysis results show Tedopi was associated with a 12-month survival rate of 46% (29/63) vs 36% (13/36) in the chemotherapy control arm. Patient screening and accrual into Step-2 has been terminated due to the Covid-19 pandemic.

SPS commentary:

Tedopi is a vaccine targeting five tumour-associated antigens found in various tumours. The current study was investigating its use in the treatment of patients with NSCLC after failure of immune checkpoint inhibitors. It is also being studied in pancreatic cancer, in combination with nivolumab.

Biospace Inc.